Noble

Lobe Sciences Announces Frederick D. Sancilio Ph.D. to Join Board of Directors

Retrieved on: 
星期五, 五月 31, 2024
Biotechnology, Neurology, Mental Health, Health, Pharmaceutical, State university system, Translation, Intellectual property, Commercialization, Biochemistry, Retirement, SCI, US FDA, Medical food, Sickle cell disease, Mental health, Capital market, Substance abuse, Analytical chemistry, Rutgers University, Research, Division, DSM-IV codes, Noble, OTCQB, Florida Atlantic University, Plasma protein binding, Pharmaceutical industry

Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors.

Key Points: 
  • Lobe Sciences Ltd. (OTCQB: LOBEF) (CSE: LOBE) ("Lobe" or the "Company"), a biopharmaceutical company focused on developing transformative medicines to treat rare diseases today announced that Frederick D. Sancilio Ph.D. has agreed to join its Board of Directors.
  • Dr. Sancilio brings over four decades of successful experience in pharmaceutical sciences and biopharmaceutical research, further strengthening Lobe Sciences' commitment to pioneering advancements in mental health and wellness.
  • “We are delighted to welcome Dr. Sancilio to our Board of Directors,” said Philip J.
  • “I am excited to join Lobe Sciences and contribute to its innovative approach to mental health treatment," said Dr. Sancilio.

One of 2024's Must Read Autobiographies on Overcoming Hardship and Difficulties Is 'We All Have a Story! Here's Mine.' by Author Maurice Chandler

Retrieved on: 
星期六, 四月 20, 2024
Amazon (company), City, Thought, Happiness, Audible, Emotion, Life, Amazon, Autobiography, Noble, Running, Book

The Autobiography of Maurice Chandler continues to captivate readers with its heartfelt insights and powerful life lessons.

Key Points: 
  • The Autobiography of Maurice Chandler continues to captivate readers with its heartfelt insights and powerful life lessons.
  • This fascinating book is a whirlwind of emotions that keeps readers engaged with laughs, sorrows, and suspense.
  • The Autobiography of Maurice Chandler is perfect for readers who enjoy human-interest stories and real-life redemption arcs.
  • The Autobiography of Maurice Chandler is available for purchase on Amazon.com , Lulu.com , Barnes and Noble or wherever books are sold.

Sonnenblick-Eichner Company Arranges a Strategic Joint Venture Equity Investment For the Pacific City Lodging Portfolio, Pacific City, Oregon

Retrieved on: 
星期一, 四月 22, 2024
Noble House, Pacific Ocean, Partnership, Collection, House, Oregon Coast, Nestucca River, Noble, Growth

LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- Sonnenblick-Eichner Company has arranged a strategic joint venture equity investment into the ownership entity of the Pacific City Lodging Portfolio, located in Pacific City, Oregon. The Pacific City Lodging Portfolio is an irreplaceable collection of iconic oceanfront resort properties comprised of the Headlands Coastal Lodge & Spa, the Inn at Cape Kiwanda, Hart’s Camp, and the Cape Kiwanda RV Park. Noble House Hotels & Resorts of Kirkland, Washington provided the investment into the partnership.

Key Points: 
  • LOS ANGELES, April 22, 2024 (GLOBE NEWSWIRE) -- Sonnenblick-Eichner Company has arranged a strategic joint venture equity investment into the ownership entity of the Pacific City Lodging Portfolio, located in Pacific City, Oregon.
  • The Pacific City Lodging Portfolio is an irreplaceable collection of iconic oceanfront resort properties comprised of the Headlands Coastal Lodge & Spa, the Inn at Cape Kiwanda, Hart’s Camp, and the Cape Kiwanda RV Park.
  • Noble House Hotels & Resorts of Kirkland, Washington provided the investment into the partnership.
  • Pacific City is recognized as the premier destination on the Oregon Coast for outdoor activities and experiential leisure travel.

IN8bio to Present at Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Retrieved on: 
星期二, 四月 16, 2024
Webcast, Catalog, Noble, Conference, Interest, Q&A

NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.

Key Points: 
  • NEW YORK, April 16, 2024 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB) a clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced that William Ho, CEO and Co-founder, will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18th at 12:30pm ET.
  • The formal presentation will feature a fireside style Q&A session with questions welcome from the live virtual audience.
  • Attendees interested in viewing the live presentation can register for this event here: Virtual Healthcare Equity Conference Registration .
  • The IN8bio management team will also be hosting one-on-one meetings during the virtual event with registered, qualified investor attendees.

Ocugen to Participate in Fireside Chat at the Emerging Growth Virtual Healthcare Equity Conference, Presented by Noble Capital Markets

Retrieved on: 
星期五, 四月 12, 2024
FDA, Retinitis pigmentosa, Capital market, Conference, Webcast, Vaccine, Entrepreneurship, Patient, Noble

MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024.

Key Points: 
  • MALVERN, Pa., April 12, 2024 (GLOBE NEWSWIRE) -- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell therapies, and vaccines, today announced that Dr. Shankar Musunuri, Chairman, CEO, and Co-Founder will participate in a fireside chat during the Emerging Growth Virtual Healthcare Equity Conference, presented by Noble Capital Markets, taking place from April 17 – 18, 2024.
  • Details of the fireside chat are as follows:
    During the fireside chat and one-on-one sessions, Dr. Musunuri will showcase the Company’s recent business and clinical development progress including FDA clearance to initiate a Phase 3 clinical trial for OCU400—a modifier gene therapy for patients battling retinitis pigmentosa (RP).
  • OCU400 is the first gene therapy to enter a late-stage trial with a broad RP indication.
  • The webcast will be archived on the Company's website for 90 days following the event.

Atossa to Participate in Noble Capital Markets Emerging Growth Healthcare Conference

Retrieved on: 
星期四, 四月 11, 2024
Noble, Atossa, Therapy, Conference, Breast cancer

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET.

Key Points: 
  • SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) (“Atossa” or the “Company”) today announced that Chief Executive Officer Steven Quay, M.D., Ph.D., will speak at the Noble Capital Markets Emerging Growth Healthcare Conference on Wednesday, April 17 at 9:00 am ET.
  • The presentation will be available virtually and members of the Company’s leadership team will be available for one-on-one meetings with registered investors of the conference.
  • Atossa is a clinical stage biopharmaceutical company developing innovative medicines in areas of significant unmet medical need in oncology with a focus on breast cancer.
  • Individuals interested in viewing the live presentation can register for the free event here: Noble Healthcare Conference Registration .

Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference

Retrieved on: 
星期四, 四月 11, 2024
Rett syndrome, Doctor of Philosophy, Conference, CNS, Schizophrenia, Therapy, DSM-IV codes, Central nervous system, Noble

NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.

Key Points: 
  • NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental disorders including Alzheimer’s disease, Parkinson’s disease, Rett syndrome, schizophrenia and other central nervous system (CNS) diseases, today announced that it will present at the Noble Capital Markets Virtual Healthcare Equity Conference.
  • Christopher U Missling, PhD, President & Chief Executive Officer is scheduled to present at 1:30pm ET, TRACK 2 on Thursday, April 18th, 2024.
  • A live audio webcast will be accessible through the Investors section of the Company’s website at www.anavex.com .
  • An archived edition of the session will be available later that day.

SeaStar Medical to Present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference

Retrieved on: 
星期四, 四月 11, 2024
Noble, Conference

DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time.

Key Points: 
  • DENVER, April 11, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage medical device company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs, announces that management will present at the Noble Capital Markets’ Emerging Growth Virtual Healthcare Equity Conference on Thursday, April 18 at 9:30 a.m. Eastern time.
  • The formal presentation will be followed by a hosted question-and-answer session.
  • Investors interested in viewing the live presentation can register for this event here: Virtual Healthcare Equity Conference Registration .
  • An archived replay will be available on the Company’s website approximately 48 hours after the live event and will be archived for 90 days.

Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference

Retrieved on: 
星期三, 四月 10, 2024
Kidney disease, Noble, Therapy, Patient, Conference, Webcast, LOS

LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m.

Key Points: 
  • LOS ALTOS, Calif., April 10, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today announced that Shalabh Gupta, M.D., Chief Executive Officer will present a company update at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on Thursday April 18, 2024 at 11:00 a.m.
  • ET.
  • A link to the live and archived webcast may be accessed on the Unicycive website under the Investors section: Events and Presentations .
  • An archive of the webcast will be available for three months.

Canada Nickel Announces Exercise of Mann Property Option with Noble

Retrieved on: 
星期一, 四月 22, 2024
Points of the compass, CNC, Exercise, Noble, TSX Venture Exchange

Northwest and Central will advance to resource delineation programs while Southeast will be drilled for the first time, all during the 2024 exploration program

Key Points: 
  • Northwest and Central will advance to resource delineation programs while Southeast will be drilled for the first time, all during the 2024 exploration program
    TORONTO, April 22, 2024 /PRNewswire/ - Canada Nickel Company Inc. ("Canada Nickel" or the "Company") (TSXV: CNC) (OTCQX: CNIKF) is pleased to announce that it is exercising its option to acquire an 80% interest in the Mann Nickel Property from Noble Mineral Exploration Inc. ("Noble") as Canada Nickel consolidates its interests in bulk tonnage nickel projects east of Timmins, Ontario.
  • Mark Selby, CEO of Canada Nickel, commenting on the exercise of the option said, "We are pleased to complete the option agreement with Noble after our successful drill program in 2023 where all 15 holes intersected target mineralization.
  • We are looking forward to further unlocking the potential of these three targets in 2024."
  • The completion of any transactions mentioned in this release is subject to customary closing conditions, including final TSX Venture Exchange approval.